Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKN1 | Q16512 | 2/20 | 0.34 |
| ▸ | PAK4 | O96013 | 1/20 | 0.34 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.33 |
| ▸ | TNK2 | Q07912 | 6/20 | 0.32 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.32 |
| ▸ | CDK4 | P11802 | 2/20 | 0.32 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.32 |
| ▸ | FGFR2 | P21802 | 2/20 | 0.32 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.32 |
| ▸ | FGFR3 | P22607 | 2/20 | 0.32 |
| ▸ | CCND1 | P24385 | 2/20 | 0.32 |
| ▸ | CDK2 | P24941 | 2/20 | 0.32 |
| ▸ | PAK3 | O75914 | 2/20 | 0.32 |
| ▸ | PAK1 | Q13153 | 2/20 | 0.32 |
| ▸ | PAK2 | Q13177 | 2/20 | 0.32 |
| ▸ | WEE1 | P30291 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15035652 | 0.80 | EGFR (0.36) | PKN1PAK4PTK2TNK2FGFR1 | |
| SCHEMBL15034893 | 0.80 | PAK4 (0.38) | PKN1PAK4TNK2FGFR1CDK4 | |
| SCHEMBL15035902 | 0.77 | JAK2 (0.37) | PKN1PAK4PTK2TNK2FGFR1 | |
| SCHEMBL15034973 | 0.76 | PAK4 (0.39) | PKN1PAK4TNK2FGFR1CDK4 | |
| SCHEMBL15035891 | 0.76 | TNK2 (0.35) | TNK2FGFR1CDK4CCNA2FGFR2 | |
| SCHEMBL15034783 | 0.76 | PAK4 (0.39) | PKN1PAK4PTK2FGFR1CDK4 | |
| SCHEMBL15035871 | 0.73 | CSF1R (0.35) | PKN1PAK4PTK2FGFR1CDK4 | |
| SCHEMBL15035852 | 0.73 | TNK2 (0.36) | TNK2FGFR1CDK4CCND1 | |
| SCHEMBL15041884 | 0.73 | TNK2 (0.36) | PKN1PAK4PTK2TNK2FGFR1 | |
| SCHEMBL15034912 | 0.72 | RIPK2 (0.36) | TNK2FGFR1CDK4CCNA2FGFR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130252967-A1 | 8-(SULFONYLBENZYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130252967-A1 | 8-(SULFONYLBENZYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | AFRAXIS, INC. (US) | 2013-09-26 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | AFRAXIS, INC. (US) | 2013-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252967-A1 | 8-(SULFONYLBENZYL)PYRIDO[2,3-D]PYRIMIDIN-7(8H)-ONES FOR THE TREATMENT OF CNS DISORDERS | PAK2, PAK3, PAK6 | PKN1 430/4885PAK4 5/4885PTK2 166/4885 |
| US-20130158043-A1 | PAK INHIBITORS FOR THE TREATMENT OF CANCER | PAK5, PAK2, PAK6 | PKN1 326/4885PAK4 5/4885PTK2 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.